Format

Send to

Choose Destination
Transfus Clin Biol. 2011 Apr;18(2):53-61. doi: 10.1016/j.tracli.2011.02.023. Epub 2011 Apr 6.

[Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].

[Article in French]

Author information

1
Établissement français du sang Alsace, 10, rue Spielmann, BP 36, 67065 Strasbourg cedex, France. jeanpierre.cazenave@efs-alsace.fr

Abstract

The transfusion of labile blood products is vital and essential for patients in absence of alternative treatment. Patients and doctors have always feared transfusion-transmitted infections by blood, blood components and blood-derived drugs. Photochemical inactivation of platelet concentrates and plasma, using a technique associating amotosalen and UVA, has been used for five years in a French region for the whole population and a large spectrum of patients, with efficacy and safety. It would seem wise to introduce labile blood products, submitted to pathogen inactivation by a technique already approved by a regulatory agency and not to wait for a perfect system including red blood cells concentrates. Universal implementation of pathogen inactivation in labile blood products is a major and key step to improve safety against infection in transfusion.

PMID:
21474358
DOI:
10.1016/j.tracli.2011.02.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center